Zobrazeno 1 - 10
of 423
pro vyhledávání: '"Barst, RJ"'
Autor:
Rubin LJ, Badesch DB, Fleming TR, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic Pehar M, McLaughlin VV, Barst RJ, behalf of the SUPER 2 Study Group, GALIE', NAZZARENO
Publikováno v:
Chest. 140(5)
Background: The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed. Methods: Two hundred fifty-nine of 277 randomized and treated patients completed a 12-week, double-blind, placebo-contro
Autor:
GALIE', NAZZARENO, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ
Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. Methods and Results-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::3f9896d612680246839a3657c36ce0bd
http://hdl.handle.net/11585/76279
http://hdl.handle.net/11585/76279
Autor:
Benza RL, Barst RJ, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R., GALIE', NAZZARENO
Publikováno v:
Chest. 134(4)
Despite advances in the management of pulmonary arterial hypertension (PAH), the mortality rate remains excessive. Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational
Autor:
Simonneau G, Rubin LJ, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, GALIE', NAZZARENO
Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension. OBJECTIVE: To investigate the effect of adding oral sildenafil to long-term intravenous epoprostenol in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::efca4359200f69c7429392969811e25e
http://hdl.handle.net/11585/76286
http://hdl.handle.net/11585/76286
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exercise capacity and hemodynamics in PAH, and increases survival in idiopathic PAH (IPAH). To evaluate the effects of subcutaneous (SC) treprostinil, a lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::81b7fb0c2ed7c7842c91214ef31bf42c
http://hdl.handle.net/11585/30336
http://hdl.handle.net/11585/30336
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprostinil, a stable prostacyclin analogue, for treating pulmonary arterial hypertension (PAH) in patients with connective tissue disease (CTD). DESIGN: Two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::731d0384f45991e05b268101cefe8d7e
http://hdl.handle.net/11585/24902
http://hdl.handle.net/11585/24902
Autor:
Barst Rj
Publikováno v:
Thorax. 55:95-96
Primary pulmonary hypertension is characterised by a progressive increase in pulmonary artery pressure which eventually leads to right ventricular failure and death. Patients with severe right heart failure—for example, New York Heart Association f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.